eluxadoline (Viberzi)
Jump to navigation
Jump to search
Indications
Contraindications
- history of bile duct obstruction
- history of pancreatitis
- history of cholecystectomy
- severe liver impairment
- severe constipation
- > 3 alcoholic beverages per day
Dosage
Tabs: 75 mg
Adverse effects
- constipation
- nausea
- abdominal pain
- spasm in the sphincter of Oddi, resulting in pancreatitis
- increased risk of pancreatitis in patients without a gallbladder[3]
Mechanism of action
- activates receptors in the nervous system that can lessen bowel contractions
- mixed opioid effects[2]
More general terms
References
- ↑ 1.0 1.1 FDA News Release. May 27, 2015 FDA approves two therapies to treat IBS-D http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.htm
- ↑ 2.0 2.1 2.2 Lembo AJ, Lacy BE, Zuckerman MJ et al Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med 2016; 374:242-253. January 21, 2016 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26789872 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1505180
- ↑ 3.0 3.1 FDA Safety Alert. 03/15/2017 Viberzi (eluxadoline): Drug Safety Communication - Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm546771.htm